Sun Pharma gets tentative FDA nod for generic Gemzar
Sun Pharmaceutical Industries has received tentative approval from the FDA for the Abbreviated New Drug Application (ANDA) for its generic version of Eli Lilly’s cancer drug, Gemzar. The generic gemcitabine injections are therapeutic equivalents of Eli Lilly’s Gemzar injections and are available in strengths of 200 mg and 1g single use vial.
- FDA approves generic Casodex
- Teva receives approval for generic Eloxatin
- Spectrum Pharma receives FDA approval for Zevalin
- Spectrum Pharma Fusilev fails to get FDA approval as metastatic colorectal cancer treatment
